Newsfeeds - Spark Newswire

4 minute read

GBT Presented Positive New Data on Oxbryta (voxelotor) in Patients with Sickle Cell Disease at ASH 2021; Said Real-world Experience Study of More Than 3,100 Patients Demonstrates Statistically Significant Reductions in Transfusions, Vaso-occlusive Cris…

Today, 5:51 AM

lobal Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced positive results from real-world and long-term studies with Oxbryta® (voxelotor) tablets for the treatment of sickle cell disease (SCD).

GBT

2 minute read

Earnings

Global Blood Therapeutics Earnings Perspective: Return On Capital Employed

By Benzinga Insights

Today, 5:51 AM

Benzinga Pro data, Global Blood Therapeutics (NASDAQ:GBT) reported Q3 sales of $52.05 million. Earnings fell to a loss of $70.99 million, resulting in a 2.01% decrease from last quarter.

GBT

11 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For December 7, 2021

By Benzinga Insights

Today, 5:51 AM

APD

1 minute read

William Blair Upgrades Global Blood Therapeutics to Outperform

By Benzinga Newsdesk

Today, 5:51 AM

William Blair analyst Raju Prasad upgrades Global Blood Therapeutics (NASDAQ:GBT) from Market Perform to Outperform.

GBT

6 minute read

Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates

By Shanthi Rexaline

Today, 5:51 AM

A majority of verdicts handed down by the FDA in November were positive. Three new molecular entities were approved during the month, taking the total number of NME approvals for the year-to-date period to 45. This is just one short of NME approvals received for the same period last year.

ABBV

1 minute read

RBC Capital Maintains Outperform on Global Blood Therapeutics, Lowers Price Target to $64

By Benzinga Newsdesk

Today, 5:51 AM

RBC Capital analyst Gregory Renza maintains Global Blood Therapeutics (NASDAQ:GBT) with a Outperform and lowers the price target from $66 to $64.

GBT

1 minute read

Global Blood Therapeutics Q3 EPS $(1.13) Misses $(1.11) Estimate, Sales $52.05M Miss $53.70M Estimate

By Benzinga Newsdesk

Today, 5:51 AM

Global Blood Therapeutics (NASDAQ:GBT) reported quarterly losses of $(1.13) per share which missed the analyst consensus estimate of $(1.11) by 1.8 percent. This is a 16.49 percent decrease over losses of $(0.97) per

GBT

32 minute read

Earnings Scheduled For November 4, 2021

By Benzinga Insights

Today, 5:51 AM

Companies Reporting Before The Bell • DISH Network (NASDAQ:DISH) is likely to report quarterly earnings at $0.91 per share on revenue of $4.45 billion.

AAOI

7 minute read

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline

By Shanthi Rexaline

Today, 5:51 AM

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.

ADPT

1 minute read

See Why Jefferies Sees Massive Upside In Global Blood Therapeutics

By Vandana Singh

Today, 5:51 AM

Jefferies initiated coverage of Global Blood Therapeutics Inc (NASDAQ:GBT) with a Buy rating and $68 price target. The analyst sees an upside…

GBT